COVID-19 and HSCT (Hematopoietic stem cell transplant).
Best Pract Res Clin Haematol
; 35(3): 101399, 2022 Sep.
Article
in English
| MEDLINE | ID: covidwho-2060442
ABSTRACT
HSCT recipients are at increased risk for COVID-19-associated morbidity and mortality. Early treatment of symptomatic SARS-CoV-2 infection is an important means to decreasing risk for severe disease and death. While some HSCT recipients, particularly those who are early post-transplant and severely immunosuppressed, may have diminished response to COVID-19 vaccines, the benefits of vaccination are uncontested. Public health, healthcare facility and individual level approaches are all necessary to mitigate risk for infection in this vulnerable population.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Hematopoietic Stem Cell Transplantation
/
COVID-19
Type of study:
Prognostic study
Topics:
Long Covid
/
Vaccines
Limits:
Humans
Language:
English
Journal:
Best Pract Res Clin Haematol
Journal subject:
Hematology
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS